165 related articles for article (PubMed ID: 30337526)
21. BTK modulates p73 activity to induce apoptosis independently of p53.
Rada M; Barlev N; Macip S
Cell Death Discov; 2018; 4():30. PubMed ID: 30245853
[TBL] [Abstract][Full Text] [Related]
22. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
Guo X; Yang D; Fan Z; Zhang N; Zhao B; Huang C; Wang F; Ma R; Meng M; Deng Y
Eur J Med Chem; 2019 Sep; 178():767-781. PubMed ID: 31234030
[TBL] [Abstract][Full Text] [Related]
23. Bruton Tyrosine Kinase Inhibitors: Present and Future.
Burger JA
Cancer J; 2019; 25(6):386-393. PubMed ID: 31764119
[TBL] [Abstract][Full Text] [Related]
24. Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
Ran F; Liu Y; Liu M; Zhang D; Wang P; Dong J; Tang W; Zhao G
Bioorg Chem; 2019 Aug; 89():102943. PubMed ID: 31031018
[TBL] [Abstract][Full Text] [Related]
25. The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.
Rip J; Van Der Ploeg EK; Hendriks RW; Corneth OBJ
Crit Rev Immunol; 2018; 38(1):17-62. PubMed ID: 29717662
[TBL] [Abstract][Full Text] [Related]
26. A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2.
Takata M; Kurosaki T
J Exp Med; 1996 Jul; 184(1):31-40. PubMed ID: 8691147
[TBL] [Abstract][Full Text] [Related]
27. Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.
Hu N; Wang F; Sun T; Xu Z; Zhang J; Bernard D; Xu S; Wang S; Kaminski M; Devata S; Phillips T; Malek SN
Clin Cancer Res; 2021 Apr; 27(8):2301-2313. PubMed ID: 33419778
[TBL] [Abstract][Full Text] [Related]
28. Fortifying p53 - beyond Mdm2 inhibitors.
Sriraman A; Li Y; Dobbelstein M
Aging (Albany NY); 2016 Sep; 8(9):1836-1837. PubMed ID: 27688014
[No Abstract] [Full Text] [Related]
29. SDF1α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA.
Nimmagadda SC; Frey S; Müller P; Wolleschak D; Weinert S; Keller U; Edelmann B; Fischer T
Haematologica; 2019 Jul; 104(7):e288-e292. PubMed ID: 30765477
[No Abstract] [Full Text] [Related]
30. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
31. Amelioration of age-related brain function decline by Bruton's tyrosine kinase inhibition.
Ekpenyong-Akiba AE; Poblocka M; Althubiti M; Rada M; Jurk D; Germano S; Kocsis-Fodor G; Shi Y; Canales JJ; Macip S
Aging Cell; 2020 Jan; 19(1):e13079. PubMed ID: 31736210
[TBL] [Abstract][Full Text] [Related]
32. An essential role for Bruton's [corrected] tyrosine kinase in the regulation of B-cell apoptosis.
Anderson JS; Teutsch M; Dong Z; Wortis HH
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10966-71. PubMed ID: 8855292
[TBL] [Abstract][Full Text] [Related]
33. Bruton's tyrosine kinase mediates NF-kappa B activation and B cell survival by B cell-activating factor receptor of the TNF-R family.
Shinners NP; Carlesso G; Castro I; Hoek KL; Corn RA; Woodland RT; Scott ML; Wang D; Khan WN
J Immunol; 2007 Sep; 179(6):3872-80. PubMed ID: 17785824
[TBL] [Abstract][Full Text] [Related]
34. PI3K/AKT and Mdm2 activation are associated with inhibitory effect of cAMP increasing agents on DNA damage-induced cell death in human pre-B NALM-6 cells.
Ghorbani A; Jeddi-Tehrani M; Saidpour A; Safa M; Bayat AA; Zand H
Arch Biochem Biophys; 2015 Jan; 566():58-66. PubMed ID: 25524737
[TBL] [Abstract][Full Text] [Related]
35. The Development of BTK Inhibitors: A Five-Year Update.
Tasso B; Spallarossa A; Russo E; Brullo C
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885993
[TBL] [Abstract][Full Text] [Related]
36. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Guo Y; Liu Y; Hu N; Yu D; Zhou C; Shi G; Zhang B; Wei M; Liu J; Luo L; Tang Z; Song H; Guo Y; Liu X; Su D; Zhang S; Song X; Zhou X; Hong Y; Chen S; Cheng Z; Young S; Wei Q; Wang H; Wang Q; Lv L; Wang F; Xu H; Sun H; Xing H; Li N; Zhang W; Wang Z; Liu G; Sun Z; Zhou D; Li W; Liu L; Wang L; Wang Z
J Med Chem; 2019 Sep; 62(17):7923-7940. PubMed ID: 31381333
[TBL] [Abstract][Full Text] [Related]
37. Complementary roles for CD19 and Bruton's tyrosine kinase in B lymphocyte signal transduction.
Fujimoto M; Poe JC; Satterthwaite AB; Wahl MI; Witte ON; Tedder TF
J Immunol; 2002 Jun; 168(11):5465-76. PubMed ID: 12023340
[TBL] [Abstract][Full Text] [Related]
38. The protein product of the c-cbl protooncogene is phosphorylated after B cell receptor stimulation and binds the SH3 domain of Bruton's tyrosine kinase.
Cory GO; Lovering RC; Hinshelwood S; MacCarthy-Morrogh L; Levinsky RJ; Kinnon C
J Exp Med; 1995 Aug; 182(2):611-5. PubMed ID: 7629518
[TBL] [Abstract][Full Text] [Related]
39. Functions of p53 in metabolism and invasion.
Vousden KH
Biochem Soc Trans; 2009 Jun; 37(Pt 3):511-7. PubMed ID: 19442244
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
Zheng N; Hao Q; Lin K; Pan J; Li Y; Zhou W
Bioorg Med Chem Lett; 2019 Jan; 29(2):225-229. PubMed ID: 30522954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
